PT3474850T - Composição intranasal compreendendo beta-histina - Google Patents

Composição intranasal compreendendo beta-histina

Info

Publication number
PT3474850T
PT3474850T PT187037494T PT18703749T PT3474850T PT 3474850 T PT3474850 T PT 3474850T PT 187037494 T PT187037494 T PT 187037494T PT 18703749 T PT18703749 T PT 18703749T PT 3474850 T PT3474850 T PT 3474850T
Authority
PT
Portugal
Prior art keywords
betahistine
intranasal composition
intranasal
composition
Prior art date
Application number
PT187037494T
Other languages
English (en)
Original Assignee
Otolanum Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otolanum Ag filed Critical Otolanum Ag
Publication of PT3474850T publication Critical patent/PT3474850T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT187037494T 2017-02-02 2018-02-02 Composição intranasal compreendendo beta-histina PT3474850T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762453931P 2017-02-02 2017-02-02

Publications (1)

Publication Number Publication Date
PT3474850T true PT3474850T (pt) 2020-07-27

Family

ID=61187302

Family Applications (2)

Application Number Title Priority Date Filing Date
PT187037494T PT3474850T (pt) 2017-02-02 2018-02-02 Composição intranasal compreendendo beta-histina
PT201704483T PT3698791T (pt) 2017-02-02 2018-02-02 Composição intranasal compreendendo beta-histina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT201704483T PT3698791T (pt) 2017-02-02 2018-02-02 Composição intranasal compreendendo beta-histina

Country Status (34)

Country Link
US (2) US10456386B2 (pt)
EP (2) EP3698791B1 (pt)
JP (3) JP2020506930A (pt)
KR (1) KR102653545B1 (pt)
CN (1) CN110418643A (pt)
AR (1) AR111699A1 (pt)
AU (1) AU2018216970B2 (pt)
BR (1) BR112019015687A2 (pt)
CA (1) CA3051725A1 (pt)
CL (1) CL2019002145A1 (pt)
CO (1) CO2019008657A2 (pt)
DK (2) DK3698791T3 (pt)
EA (1) EA201991817A1 (pt)
ES (1) ES2807798T3 (pt)
FI (1) FI3698791T3 (pt)
HR (2) HRP20231706T1 (pt)
HU (1) HUE050829T2 (pt)
IL (1) IL268353B2 (pt)
LT (2) LT3474850T (pt)
MA (1) MA46778B1 (pt)
MX (1) MX2019008961A (pt)
MY (1) MY196333A (pt)
NZ (1) NZ755931A (pt)
PH (1) PH12019501785A1 (pt)
PL (2) PL3698791T3 (pt)
PT (2) PT3474850T (pt)
RS (2) RS60554B1 (pt)
SA (1) SA519402324B1 (pt)
SG (1) SG11201906980YA (pt)
SI (1) SI3474850T1 (pt)
TN (1) TN2019000220A1 (pt)
TW (1) TWI760429B (pt)
WO (1) WO2018141922A1 (pt)
ZA (1) ZA201904955B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170532A1 (en) * 2017-03-22 2018-09-27 Franz, Lilian Ann Treatment method
CA3179806A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Nasal spray formulation with moisturizing benefits

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2397840B1 (pt) 1977-07-22 1981-03-20 Cherqui Jean
IT1229237B (it) * 1989-05-08 1991-07-26 Prodotti Formenti Sali di (2-(piridil)etil) metilammina
JPH03287535A (ja) * 1990-03-31 1991-12-18 Bairon Boeki Kk プラノプロフェン水溶液
JP3203056B2 (ja) * 1992-08-13 2001-08-27 株式会社ティ・ティ・エス技術研究所 メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
JPH10139667A (ja) * 1996-11-15 1998-05-26 Yoshitomi Pharmaceut Ind Ltd 水性液剤
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
JP3555598B2 (ja) 2001-06-27 2004-08-18 株式会社村田製作所 積層型インダクタ
JP2004196676A (ja) * 2002-12-16 2004-07-15 Rohto Pharmaceut Co Ltd 点鼻剤
JP4733333B2 (ja) * 2002-12-26 2011-07-27 ライオン株式会社 点鼻剤又は洗鼻剤
SI1530965T1 (sl) 2003-11-11 2006-06-30 Mattern Udo Formulacija za nasalno aplikacijo z nadzorovanim sproscanjem spolnih hormonov
AU2006202950A1 (en) * 2004-04-22 2006-10-19 Mor Research Applications Ltd. Methods and Compositions for Weight Management
CA2553309A1 (en) * 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
EP2457580A1 (en) 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration
JP2009504767A (ja) * 2005-08-17 2009-02-05 フレミング・アンド・カンパニー・ファーマシューティカルズ ビタミンb12鼻用スプレーおよび使用方法
WO2007076140A2 (en) 2005-12-23 2007-07-05 University Of Cincinnati Treatment methods employing histamine h3 receptor antagonists, including betahistine
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
RU2010129833A (ru) * 2007-12-21 2012-01-27 Шеринг-Плау Хельскер Продактс, Инк. (Us) Повышение светоустойчивости оксиметазолина
MX2010011545A (es) * 2008-04-21 2011-04-11 Otonomy Inc Formulaciones para tratar enfermedades y afecciones del oido.
CN102046170B (zh) * 2008-05-27 2012-11-28 墨尔本大学 治疗患有咽鼓管功能障碍的哺乳动物的方法
BRPI0919811B1 (pt) * 2008-10-08 2022-04-19 Xgene Pharmaceutical Inc Conjugados de gaba e métodos de uso dos mesmos
EP3200828B1 (en) * 2014-10-03 2020-08-12 Lachesis Biosciences Limited Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Also Published As

Publication number Publication date
SG11201906980YA (en) 2019-08-27
MA46778A1 (fr) 2021-04-30
WO2018141922A1 (en) 2018-08-09
US10456386B2 (en) 2019-10-29
CO2019008657A2 (es) 2020-01-17
MY196333A (en) 2023-03-24
TN2019000220A1 (en) 2021-01-07
BR112019015687A2 (pt) 2020-04-28
PL3698791T3 (pl) 2024-04-08
IL268353A (en) 2019-09-26
LT3474850T (lt) 2020-08-10
HRP20201137T1 (hr) 2021-01-22
HRP20231706T1 (hr) 2024-03-15
AU2018216970A1 (en) 2019-08-22
EP3698791A1 (en) 2020-08-26
DK3474850T3 (da) 2020-08-03
MA46778B1 (fr) 2022-08-31
NZ755931A (en) 2022-07-29
ZA201904955B (en) 2021-05-26
LT3698791T (lt) 2024-02-12
US20200022963A1 (en) 2020-01-23
CN110418643A (zh) 2019-11-05
AR111699A1 (es) 2019-08-14
EA201991817A1 (ru) 2020-01-27
SI3474850T1 (sl) 2020-09-30
EP3474850B1 (en) 2020-04-22
JP2024019731A (ja) 2024-02-09
TW201831179A (zh) 2018-09-01
KR102653545B1 (ko) 2024-04-04
RS65099B1 (sr) 2024-02-29
IL268353B1 (en) 2023-06-01
US20180214432A1 (en) 2018-08-02
EP3474850A1 (en) 2019-05-01
RS60554B1 (sr) 2020-08-31
JP2022051872A (ja) 2022-04-01
CA3051725A1 (en) 2018-08-09
PH12019501785A1 (en) 2020-07-06
FI3698791T3 (fi) 2024-01-11
KR20190116341A (ko) 2019-10-14
DK3698791T3 (da) 2024-01-15
EP3698791B1 (en) 2023-10-25
JP2020506930A (ja) 2020-03-05
ES2807798T3 (es) 2021-02-24
TWI760429B (zh) 2022-04-11
PL3474850T3 (pl) 2020-09-21
SA519402324B1 (ar) 2023-03-16
PT3698791T (pt) 2024-01-12
MX2019008961A (es) 2019-10-15
CL2019002145A1 (es) 2019-11-04
HUE050829T2 (hu) 2021-01-28
AU2018216970B2 (en) 2023-12-21
IL268353B2 (en) 2023-10-01

Similar Documents

Publication Publication Date Title
PL3697376T3 (pl) Kompozycja
GB201703455D0 (en) Composition
GB2562466B (en) Composition
GB201719139D0 (en) Composition
GB201700504D0 (en) Composition
GB201713636D0 (en) Composition
GB201712151D0 (en) Composition
IL268353A (en) The intranasal composition includes betahistine
GB201707238D0 (en) Composition
GB201702833D0 (en) Composition
GB201816988D0 (en) Composition
LT3576546T (lt) Probiotikų kompozicija
GB201721674D0 (en) Composition
GB201718871D0 (en) Composition
GB201715135D0 (en) Composition
GB201711446D0 (en) Composition
GB201707920D0 (en) Composition
GB201710716D0 (en) Intranasal formulations
GB201701490D0 (en) Intranasal formulations
HUE063642T2 (hu) Probiotikus készítmény
GB201721675D0 (en) Composition
GB201719763D0 (en) Composition
GB201719456D0 (en) Composition
GB201717637D0 (en) Composition
GB201713225D0 (en) Composition